# DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N

> **NIH NIH N01** · EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR · 2022 · $69,278

## Abstract

The primary objective of this project is to support the advanced development of candidate products which consist of a vaccine component in combination with a technology component (a dry formulation technology) to increase stability and minimize cold chain or preservative requirements for use in post-event settings following the intentional release of or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B, and C Priority Pathogens.

## Key facts

- **NIH application ID:** 10625821
- **Project number:** 272201400038C-P00019-9999-1
- **Recipient organization:** EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR
- **Principal Investigator:** LAURENCE LEMIALE
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $69,278
- **Award type:** —
- **Project period:** 2014-08-28 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10625821

## Citation

> US National Institutes of Health, RePORTER application 10625821, DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N (272201400038C-P00019-9999-1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10625821. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*